Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 7/20 | 0.54 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751692 | 1.00 | ERBB2 (0.54) | ERBB2MINK1FFAR1MEN1KMT2A | |
| SCHEMBL5749517 | 0.93 | ERBB2 (0.54) | ERBB2MINK1FFAR1MEN1KMT2A | |
| SCHEMBL5749523 | 0.93 | ERBB2 (0.54) | ERBB2MINK1FFAR1MEN1KMT2A | |
| SCHEMBL5750044 | 0.92 | ERBB2 (0.65) | ERBB2MINK1 | |
| SCHEMBL5746616 | 0.92 | ERBB2 (0.65) | ERBB2MINK1 | |
| SCHEMBL5750040 | 0.90 | ERBB2 (0.44) | ERBB2MINK1FFAR1 | |
| SCHEMBL5750038 | 0.90 | ERBB2 (0.44) | ERBB2MINK1FFAR1 | |
| SCHEMBL5750384 | 0.89 | ERBB2 (0.47) | ERBB2MINK1FFAR1MGLL | |
| SCHEMBL5750391 | 0.89 | ERBB2 (0.47) | ERBB2MINK1FFAR1MGLL | |
| SCHEMBL6582675 | 0.88 | ERBB2 (0.57) | ERBB2MINK1FFAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984653-B2 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-10 | — | — | US | disclosed |
| US-20040242659-A1 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1439178-A1 | HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242659-A1 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | ABL1, JAK1, BTK | ERBB2 17/4885MINK1 477/4885FFAR1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.